Hézode, Christophe <br/><br/>
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.  [electronic resource] 

 -  Liver international : official journal of the International Association for the Study of the Liver  09 2017 
 - 1314-1324 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1478-3231 
<br/><br/><label>Standard No.: </label>10.1111/liv.13383  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antiviral Agents--administration & dosage<br/>Carbamates<br/>Cohort Studies<br/>Drug Therapy, Combination<br/>Female<br/>France<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--complications<br/>Humans<br/>Imidazoles--administration & dosage<br/>Liver Cirrhosis--virology<br/>Liver Transplantation--adverse effects<br/>Male<br/>Middle Aged<br/>Pyrrolidines<br/>Recurrence<br/>Ribavirin--administration & dosage<br/>Sofosbuvir--administration & dosage<br/>Sustained Virologic Response<br/>Valine--analogs & derivatives